AccurKardia, an ECG-led diagnostics software company, today announced a multi-year agreement with Lucem Health, a leading provider of clinical AI solutions. The partnership paves the way for AccurKardia to integrate its FDA-Cleared ECG Interpretation Software Platform, AccurECG™ Analysis System (“AccurECG”), into Lucem Health Reveal, a family of solutions that identify patients who may be at higher risk of severe or chronic diseases.
AccurKardia’s AccurECG is a cloud-based, device-agnostic, fully automated ECG interpretation software platform that can detect up to 13 arrhythmias. This technology assists cardiac monitoring companies in analyzing ECGs recorded from a wide array of inputs from wet electrode devices.
“Our software helps clinicians review ECGs more efficiently and enables prompt treatment of patients, with key cardiovascular insights delivered in minutes. This partnership with Lucem Health allows us to bring the power of our technology to Lucem Health’s clinical AI solution,” said Juan C. Jiménez, CEO of AccurKardia. “This is an important step in our mission to improve patients’ outcomes and save lives at scale.”
“Lucem Health’s Reveal solutions provide a unique way to identify patient health risks hiding in plain sight. Our partnership with AccurKardia enables us to extend Reveal’s benefits to cardiovascular diseases,” said Jeremy E. Pierotti, General Manager of Solutions at Lucem Health. “We’re committed to providing clinicians with the most advanced tools for early diagnosis and intervention of chronic diseases. Later this year, we’ll announce our first product incorporating AccurKardia’s FDA-cleared technology.”
About AccurKardia
AccurKardia is an ECG-led diagnostics software company unlocking the value of the ECG signal for broad diagnostics coverage and disease management ultimately improving clinical outcomes and saving lives at a planetary scale. AccurKardia’s first FDA-cleared product, AccurECG (Class II SaMD), is a cloud-based and device-agnostic software for fully automated ECG interpretation and detection for up to 13 arrhythmias. The technology assists cardiac monitoring companies in the analysis of ECGs recorded from holters, event recorders, and cardiac telemetry devices. The Company completed Cohort 3 of Mayo Clinic Platform_Accelerate in July 2023. For more information about AccurKardia, please visit: https://www.accurkardia.com/.
About Lucem Health
Lucem Health helps healthcare providers accelerate disease detection and treatment using practical, responsible AI, so they can improve patients’ lives and increase the clinical and financial yield from today’s scarce care delivery resources. We envision a world in which clinicians detect problems before they become life-threatening and patients get world-class care, everywhere. Learn more at www.lucemhealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231109975399/en/